Show simple item record

dc.contributor.authorLuzuriaga, Katherine
dc.contributor.authorBryson, Yvonne J.
dc.contributor.authorKrogstad, Paul A.
dc.contributor.authorRobinson, James E.
dc.contributor.authorStechenberg, Barbara
dc.contributor.authorLamson, Michael
dc.contributor.authorCort, Susannah
dc.contributor.authorSullivan, John L.
dc.date2022-08-11T08:09:35.000
dc.date.accessioned2022-08-23T16:36:42Z
dc.date.available2022-08-23T16:36:42Z
dc.date.issued1997-05-08
dc.date.submitted2009-04-02
dc.identifier.citationN Engl J Med. 1997 May 8;336(19):1343-9.
dc.identifier.issn0028-4793 (Print)
dc.identifier.pmid9134874
dc.identifier.urihttp://hdl.handle.net/20.500.14038/38846
dc.description.abstractBACKGROUND: In infants and children with maternally acquired human immunodeficiency virus type 1 (HIV-1) infection, treatment with a single antiretroviral agent has limited efficacy. We evaluated the safety and efficacy of a three-drug regimen in a small group of maternally infected infants. METHODS: Zidovudine, didanosine, and nevirapine were administered in combination orally to eight infants 2 to 16 months of age. The efficacy of antiretroviral treatment was evaluated by serial measurements of plasma HIV-1 RNA, quantitative plasma cultures, and quantitative cultures of peripheral-blood mononuclear cells. RESULTS: The three-drug regimen was well tolerated, without clinically important adverse events. Within four weeks, there were reductions in plasma levels of HIV-1 RNA of at least 96 percent (1.5 log) in seven of the eight study patients. Over the 6-month study period, replication of HIV-1 was controlled in two infants who began therapy at 2 1/2 months of age. Plasma RNA levels were reduced by 0.5 to 1.5 log in five of the other six infants. CONCLUSIONS: Although further observations are needed, it appears that in infants with maternally acquired HIV-1 infection, combined treatment with zidovudine, didanosine, and nevirapine is well tolerated and has sustained efficacy against HIV-1.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=9134874&dopt=Abstract">Link to Article in PubMed</a>
dc.subjectAdministration, Oral
dc.subjectAnti-HIV Agents
dc.subjectCD4 Lymphocyte Count
dc.subjectDidanosine
dc.subjectDisease Transmission, Vertical
dc.subjectDrug Therapy, Combination
dc.subjectFemale
dc.subjectHIV Infections
dc.subject*HIV-1
dc.subjectHumans
dc.subjectInfant
dc.subjectMale
dc.subjectNevirapine
dc.subjectPyridines
dc.subjectRNA, Viral
dc.subjectViral Load
dc.subjectZidovudine
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleCombination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection
dc.typeArticle
dc.source.journaltitleThe New England journal of medicine
dc.source.volume336
dc.source.issue19
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=2685&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/1686
dc.identifier.contextkey808448
refterms.dateFOA2022-08-23T16:36:42Z
html.description.abstract<p>BACKGROUND: In infants and children with maternally acquired human immunodeficiency virus type 1 (HIV-1) infection, treatment with a single antiretroviral agent has limited efficacy. We evaluated the safety and efficacy of a three-drug regimen in a small group of maternally infected infants. METHODS: Zidovudine, didanosine, and nevirapine were administered in combination orally to eight infants 2 to 16 months of age. The efficacy of antiretroviral treatment was evaluated by serial measurements of plasma HIV-1 RNA, quantitative plasma cultures, and quantitative cultures of peripheral-blood mononuclear cells. RESULTS: The three-drug regimen was well tolerated, without clinically important adverse events. Within four weeks, there were reductions in plasma levels of HIV-1 RNA of at least 96 percent (1.5 log) in seven of the eight study patients. Over the 6-month study period, replication of HIV-1 was controlled in two infants who began therapy at 2 1/2 months of age. Plasma RNA levels were reduced by 0.5 to 1.5 log in five of the other six infants. CONCLUSIONS: Although further observations are needed, it appears that in infants with maternally acquired HIV-1 infection, combined treatment with zidovudine, didanosine, and nevirapine is well tolerated and has sustained efficacy against HIV-1.</p>
dc.identifier.submissionpathoapubs/1686
dc.contributor.departmentDepartment of Pediatrics
dc.source.pages1343-9


Files in this item

Thumbnail
Name:
9134874.pdf
Size:
99.62Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record